News stories about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 47.415121085866 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Thermo Fisher Scientific (TMO) vs. Thoratec (THOR) Head-To-Head Comparison (americanbankingnews.com)
- Does Thermo Fisher Scientific Inc’s (NYSE:TMO) Recent Track Record Look Strong? (finance.yahoo.com)
- Rockwell Automation, Inc. (ROK) Ex-Dividend Date Scheduled for (nasdaq.com)
- AGCO Corporation (AGCO) Ex-Dividend Date Scheduled for February 14, 2018 – Nasdaq (nasdaq.com)
- Medtronic’s Fiscal 3Q18 Results: What to Expect (finance.yahoo.com)
Thermo Fisher Scientific (TMO) traded down $0.11 during trading hours on Friday, hitting $210.61. 895,810 shares of the stock were exchanged, compared to its average volume of 1,690,000. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. Thermo Fisher Scientific has a fifty-two week low of $151.74 and a fifty-two week high of $226.44. The firm has a market cap of $84,450.00, a PE ratio of 34.53, a PEG ratio of 1.54 and a beta of 1.11.
The business also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be paid a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is 9.84%.
TMO has been the subject of a number of analyst reports. Leerink Swann restated an “outperform” rating and set a $239.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Evercore ISI initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $220.00 price objective for the company. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Bank of America upped their price objective on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $220.50.
In other news, CFO Stephen Williamson sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the transaction, the chief financial officer now directly owns 30,741 shares of the company’s stock, valued at approximately $6,432,861.66. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the transaction, the chief executive officer now directly owns 302,577 shares in the company, valued at $58,016,113.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 94,327 shares of company stock worth $19,260,542. Corporate insiders own 0.49% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2018/02/17/thermo-fisher-scientific-tmo-receiving-somewhat-positive-news-coverage-analysis-finds.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.